DYRK1A and Alzheimer disease: With high exposure in CNS compartments across multiple species and significant pharmacodynamics response in mice, these results indicate that reducing DYRK1A activity may be a viable treatment in diseases such as AD, where an increase in enzyme activity may regulate the cascade of phosphorylation leading to tauopathies and neurodegeneration.